Aprea Therapeutics, Inc. (APRE) Institutional Ownership

Ownership Summary

A total of 22 institutions have reported a stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) as of December 2025, according to recent 13F filings with the SEC.

• Aprea Therapeutics saw its institutional ownership percentage rose to 26.8% in December 2025 from 25.6% in September 2025.
• Institutional share ownership changed by 25.98% QoQ, while the number of institutional owners saw a decrease of 18.52% YoY.
• Of these 22 institutional investors, 10 increased their holdings in Aprea Therapeutics, while 6 of them reduced positions, and 6 investors maintained their exposure.
• The total number of shares held by institutions in Aprea Therapeutics increased to 1.70Mn as of December 2025, a net change of up by 349.63K shares quarter on quarter, and down 253.91K shares year over year.
• With 370.54K shares, AIGH Capital Management LLC commands the largest institutional position in Aprea Therapeutics as of December 31, 2025, equating to 5.86% of the company.
• Among the most significant buyers of Aprea Therapeutics during December 2025 were Murchinson Ltd. (340.14K), DRW Securities, LLC (120.65K), CITADEL ADVISORS LLC (51.04K), JANE STREET GROUP, LLC (46.62K), XTX Topco Ltd (24.30K).
• Leading sellers of Aprea Therapeutics stock in December 2025 included AIGH Capital Management LLC (168.76K), VANGUARD GROUP INC (100.15K), GEODE CAPITAL MANAGEMENT, LLC (3.67K), BANK OF AMERICA CORP /DE/ (1.56K), OSAIC HOLDINGS, INC. (100).
• The top 10 institutional holders of Aprea Therapeutics for the quarter ending December 2025 included AIGH Capital Management LLC (370.54K), Murchinson Ltd. (340.14K), SPHERA FUNDS MANAGEMENT LTD. (270.00K), Nantahala Capital Management, LLC (205.76K), DRW Securities, LLC (120.65K), MORGAN STANLEY (77.03K), VANGUARD GROUP INC (58.09K), CITADEL ADVISORS LLC (51.04K), JANE STREET GROUP, LLC (46.62K), GEODE CAPITAL MANAGEMENT, LLC (40.95K).